Loading data for XFOR — first visit, this takes a few seconds.

提醒

X4 Pharmaceuticals Inc. (XFOR)

NasdaqCM: XFOR · 实时价格 · USD

4.04

-0.19 (-4.49%)

收盘价： Aug 28, 2026, 3:59 PM

4.01

-0.74%

盘后: 7:30 PM

股价、关键数字和最新消息，都在这一页。

-4.49% (1D)

买价	2.99
市值	400.55M
营收（TTM）	15.85M
净利润（TTM）	-90.14M
	0.39
	1.37
	2.95
	-5.35
市净率（TTM）	2.50
市销率（TTM）	25.28
财报日期	Nov 5, 2026

卖价	5.19
成交量	356,154
20日均量	779,219
开盘价	4.22
前收盘价	4.23
日内区间	4.00 - 4.23
52周区间	2.80 - 4.83
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 XFOR

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agre...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Nov 16, 2017

员工人数 45

交易所 NasdaqCM

股票代码 XFOR

官网 https://www.x4pharma.com

公司完整简介

财务表现

2025年，X4 Pharmaceuticals的营收为35.11M，较上一年的2.56M增长1,273.21%。净利润为-79.2M，增长111.48%。

财务报表

财报意外

X4 Pharmaceuticals 已于 Aug 6, 2026 发布季度财报：

营收为 $8.81M 低于预期 $0, ， 346.33% 同比增长.
每股收益为 -0.13 超出预期 0.05, ， 96.25% 同比增长.

下次财报发布时间

X4 Pharmaceuticals Inc. 的下次财报预计于 Nov 5, 2026, 盘中。
分析师预计营收为 ... 升级

新闻

2周前 · Zacks

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3周前 · Zacks

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3周前 · Zacks

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3月前 · Simply Wall St.

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are...

3月前 · Zacks

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

第 1 页，共 2 页

X4 Pharmaceuticals Inc. (XFOR)